engage educate evolve matt briggs ridley aqua feed novacq tm commercialization update and recent...

engage • educate • evolve

Matt Briggs Ridley Aqua Feed

NovacqTM Commercialization Update and Recent Results


Novacq™ : A revolution in shrimp production….CSIRO patented technology » Over past 10 years CSIRO developed a microbial process to

produce a non-living bioactive substance from bacterial biofloc which acts as a metabolic stimulant in crustaceans

» This process utilizes low cost agricultural by-products and fertilizers to produce a sustainable, environmentally friendly, highly effective raw material

» This bioactive is harvested, dried and included in feed for shrimp and all crustacean species i.e. f/w prawns, crayfish, crawfish, lobsters and crabs, and maybe finfish?


What does Novacq™ do ?» NovacqTM acts as a metabolic stimulant that increases food intake

and permits the animal to utilize the feed more efficiently» Because of this, the animal will grow faster (gain value &/or provide

shorter culture cycle) and use less feed (improve FCR): saving money as feed cost is the major operational cost

» Also appears to improve disease resilience and promote growth of larvae and juveniles

» Can be used to help replace fishery resources in prawn diets - important for consumers, retailers and sustainability

» And even reduce protein levels - important to help control nutrient levels in ponds and effluent discharge and minimize prodn. costs


How much Novacq™ is required ?» CSIRO have conducted a number of trials with their original product

and seen direct relationship up to 12% - but usually recommend 10% inclusion level, replacing wheat flour

» With development of new “pure” Novacq, we have now proven that can reduce to <5% of diet for same effect

» Or if use same dose, promote super-fast growth or to enable use of lower quality/cheaper diets

» This advantageous as provides more flexibility for feed formulators and is adaptable for specific applications

» NovacqTM not heat labile (survives >150oC for 12 hours without loss in performance) so can be safely included with other raw materials during diet manufacture


Basal performance

P. monodon

>90% Gain

Gai

n R

ate

(g/w

k)

Experiment 2010-1

Dose – Response curve CSIRO original NovacqTM

• All diets formulated to 42% Protein,7% Lipid• Fishmeal and wheat gluten used as main protein sources• Each treatment replicated n=5• Trial run for 35 days• Survival = 84.1 ± 1.04%

50% Gain


0 1 2 3 4 5 6 7 8 9 10 1.0

1.2

1.4

1.6

1.8

2.0

% Novacq inclusion

Me

an

we

igh

t g

ain

(g

/wk

)

P. vannamei

Basal performance

70% Gain

Dose – Response curve• All diets formulated to 47% Protein,7% Lipid• Fishmeal and wheat gluten used as main protein sources• Each treatment replicated n=5• Trial run for 40 days from 1g av wt.• Survival = 98 ± 2%

48% Gain


Trial run at CSIRO, Bribie Island over 4

weeks with 12g shrimp

Basal diet CSIRO Nov Rid Nov 1 Rid Nov 21.00

1.20

1.40

1.60

1.80

2.00

2.20 Growth of prawns fed control, CSIRO and Ridley Novacq at 10% after 28d

Gro

wth

(g

/we

ek

)

Basal diet CSIRO Nov Rid Nov 1 Rid Nov 290

100

110

120

130

140

150

160

170 Bioactivity level of Novacq from CSIRO and Ridley after 28d

Bio

ac

tiv

ity

ind

ex

(%)

Improved potency “pure”

NovacqTM

P. monodon


Latest Trial on Effects of NovacqTM on P. vannamei

• In June completed a 40d tank trial with Ridley “pure” NovacqTM in Fish Vet Group lab tank facilities in Chonburi, Thailand

• Data on growth, FCR, survival and resilience to AHPND challenge

• Tested high protein CSIRO lab diets in dose rate trial with diets containing 0-10% of NovacqTM against Thai commercial

control feedP. vannamei


Trial parameters and results• Trial used 1 g SPF P. vannamei juveniles• Each diet with 5 replicate tanks (500L) containing 10

shrimp fed each diet 4 times/day (to satiation) over a 40 day period

• Growth rate 50% increase at 5% NovacqTM and 70% increase (with 20% decrease in FCR) at 10% NovacqTM inclusion

• Also performed AHPND challenge test with shrimp fed each diet – results indicated improved resilience with increasing inclusion of NovacqTM P. vannamei


Results from Feeding trial with “pure” NovacqTM

0 2.5 5.0 7.5 10.0 Com. -

2

4

6

8

10

12

14 Mean weight after 40 days +/- SEM

% Novacq inclusion

Me

an

we

igh

t (g

)

P. vannamei


Results from Feeding trial with “pure” NovacqTM

0 2.5 5.0 7.5 10.0 Com.0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Mean survival after 40 days +/- SEM

% Novacq inclusion

% S

urv

iva

l ra

te

0 2.5 5.0 7.5 10.0 Com. -

0.20

0.40

0.60

0.80

1.00

1.20

Mean FCR after 40 days

% Novacq inclusion

FC

R

P. vannamei


Survival to AHPND challenge trial with “pure” NovacqTM

0% Novacq 2.5% Novacq 5% Novacq 7.5% Novacq 10% Novacq Commercial Unchal Control0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Su

rviv

al t

o A

HP

ND

ch

alle

ng

e P. vannamei


Effect of NovacqTM on Reducing dietary protein levels» A previous trial conducted at CSIRO looked at the effects

of varying levels of NovacqTM in diets for 3g juvenile P. monodon in clearwater laboratory tanks. Graded levels of protein in the diets were supplemented by either 0, 5 or 10% of CSIRO-produced NovacqTM

» Results after the 6 week study showed that the addition of NovacqTM improved feed intake, growth and FCR at each protein and NovacqTM inclusion level

» Results also showed that dietary protein could be offset through the inclusion of NovacqTM which results in cost savings and environmental improvements

P. monodon


30 35 40 45 50 55 600.0

0.2

0.4

0.6

0.8

1.0

1.2Novacq 0% Polynomial (Novacq 0%)Novacq 5% Linear (Novacq 5%)

Dietary Protein Content (%)

Wei

ght G

ain

(g/w

k)

P. monodon

Effect of NovacqTM on growth rate at different dietary protein levels


30 35 40 45 50 55 600

1

2

3

4

5

6 Novacq 0% Polynomial (Novacq 0%)

Dietary Protein Content (%)

FC

R

P. monodon

Effect of NovacqTM on FCR at different dietary protein levels


Effect of NovacqTM on Reducing dietary protein levels• Another recent trial conducted by CSIRO, looked at the

effects of varying levels of protein and “pure” NovacqTM in diets for 5g juvenile P. monodon in clearwater laboratory tanks.

• A constant level of protein was supplemented by graded levels of NovacqTM, and a constant level of NovacqTM was tested at various dietary protein levels to find the optimum combination

• Results after the 6 week study confirmed previous results that dietary protein levels can be reduced from 48% to 36-40% in combination with 5% NovacqTM and that growth, survival and FCR rates are actually improved

• And that increasing levels of “pure” NovacqTM up to 7.5% in the diet increased growth, survival and FCR rates, independent of dietary protein level

P. monodon


Protein 48%: Novacq 0%

Protein 48%: Novacq 2.5%


Protein 48%: Novacq 7.5%


0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

Mea

n w

eig

ht

gai

n(g

/wk)







-

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

Mea

n w

eig

ht

gai

n (

g/w

k)

Effect of NovacqTM on weight gain at different dietary protein levels

Effect of graded levels of NovacqTM at constant dietary

protein level


What does Novacq™ look like ?

Live under the microscope


China Novacq

CSIRO Novacq


What does “pure” Novacq™ look like ?On harvesting “pure”

NovacqTM in GCMA ponds

WetPartially

Dry


What does “pure” Novacq™ look like ?

After drying/processing“pure” NovacqTM

After drying

After grinding


Novacq™ Commercialization Since 2009 Ridley has been working with CSIRO to evaluate NovacqTM

and in 2013 signed an exclusive agreement to produce and market the raw material in Australia, Indonesia, Malaysia and the Philippines initially, then in 2015 added Thailand

CSIRO also signed exclusive deals with Gentech group for China and Viet Uc co. for Vietnam

Other countries will come online later – CSIRO currently considering Ecuador and Mexico and about to set up trials there

These groups are also currently producing and marketing of NovacqTM (called OBMTM in China)

To date, Ridley have refined the original production process to produce a new “pure” version on a continual basis without effluent discharge


Ridleys NovacqTM Production» At GCMA produced 3 mt of “pure” NovacqTM and 15 mt of “CSIRO-style”

mixed NovacqTM which was used in commercial trials last season (with GCMA and APF)

» Now securing second stage commercial pilot at local prawn farm where we will take experience from GCMA and scale up production to produce enough “pure” Novacq to satisfy our Australian customers (and some for Asian trials)

» Will start production this spring in 3 ha to produce 300 mt of pure NovacqTM for further trials, then expand up to 8 ha to produce 800 mt in 2016 (enough for entire Australian industry)

» Next step will be to replicate and scale up to commercial-scale farm (11 ha up to 100 ha producing 10,000 mt by 2019) in Thailand to service our Asian customers. Negotiating for site now under Thai BOI


Ridleys NovacqTM

Pond Trials


0%

20%

40%

60%

80%

100%

120%

140%

160%

180%

200%

Basal Run-1 Run-2 Commercial Commercial+

0 1 2 3 4 5 6 7 8 90

3

6

9

12

15

18

21

24

+ NovacqPolynomial (+ Novacq)Commercial Diet

Time (weeks)

Shr

imp

wei

ght (

g)R

ela

tive

Ga

in

On-Farm Data

Laboratory Data

22%

21%

5 x 1ha pond per diet

+ NovacqTM

Comm. Comm.

Survival85% Novacq78% Control

Commercial evaluation in Australia in P. monodon farm 2011/12

Using 10% of CSIRO “mixed”

NovacqTM

Pond Data

0.27 g/d

0.21 g/d


Commercial evaluation in APF P. monodon farm 2014/15

1 6 11 16 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 101 106 111 116 121 -

5

10

15

20

25

30

35

MR

MR-X

Days of culture

Mea

n w

eig

ht

(g) 3 x 1 ha pond per diet

Using 10% of CSIRO “mixed”

NovacqTM

7%

Weight (g) MR (g/d) MR+ Novacq (g/d)10 0.14 0.15 15 0.19 0.19 20 0.22 0.23 25 0.24 0.25 30 0.26 0.28

Growth rate to size (g/d)


Commercial evaluation in GCMA P. monodon farm 2014/15Conducted a trial with 4 * 1 ha ponds fed Ridley MR including 10% of CSIRO-style NovacqTM against 23 * 1 ha ponds fed the same MR diet without NovacqTM

Final production rates increased by 1.6 mt/ha due largely to increased survival rates.Economic analysis of the final farm data showed that even at a 20% increase in feed cost (due to inclusion of NovacqTM) farm profit margin increased by 6% to provide an increase in revenue of nearly $14,000/1 ha pond

Density pond area Feed fed Production Production Mean wt Survival FCR DOC Growth rate

(no/m2) (ha) (mt) (mt/pond) (mt/ha) (g) (%) (days) (g/wk)

Control 41.4 0.97 22.0 14.8 15.2 46.5 81% 1.49 212 1.53

Novacq 40.1 0.94 24.6 15.8 16.8 44.5 95% 1.55 213 1.46


Future NovacqTM plans for Ridley Aqua Feed» Further refinements of pure Novacq™ production and processing

technologies together with UAT» Scaling up of “pure” Novacq™ production facilities in Australia and

Asian territories» Promotion/licensing of new technologies to current/future licensees

through CSIRO» Further testing of Novacq™ in pond feeding trials in both Australia &

Asia (shrimp and other crustaceans) with commercial partners» Introduction of product to feed mills and farmers throughout Asia» Further elucidation of the mode of action of Novacq™ on growth,

feeding efficiency & disease-resilience» Continued exploration of novel applications for the product – i.e. in

larval/brood diets & new species including finfish


Thank you

engage educate evolve matt briggs ridley aqua feed novacq tm commercialization update and recent...

Documents

gain slide

novacq tm acts

effects of novacq tm

vannamei slide

ridley pure novacq tm

trial run

monodon slide

results trial